Wow...glad to see we’re using this space for patients instead of conferences.

Learn about the 3-part system that could help beat back #COVID19, authored by our SVP of External Affairs Lauren Silvis and board member and former U.S. FDA commissioner Scott Gottlieb, MD 🇺🇸, published in Wall Street Journal Opinion: on.wsj.com/2JnnLPG.

Our CEO, Eric Lefkofsky, shared insights into how joint clinical and molecular datasets can contextualize #COVID19 test results and what we're doing to support hospitals and governments in structuring that data. Tap the link in his post to listen to the podcast from Milken Institute.

As we've been saying for some time now, accumulating data on Remdesivir suggests it's active against covid and there's now enough data to support consideration of access under an emergency use authorization by FDA. The data from NIAID study should push this firmly over the line.

In partnership with Geisinger, we conducted a cardio-focused study that demonstrated how a deep neural network can predict an important future clinical event— one-year all-cause mortality— from ECG voltage-time traces. Read the abstract in Nature Medicine: go.nature.com/2yPJ0rA

Our TIME Trial Program is revolutionizing the #ClinicalTrial model by using #GenomicProfiling and #ClinicalData to match patients to a network of 30+ sponsored biomarker trials and then rapidly open pre-qualified sites where the patient is being treated: bit.ly/3iTC0vm.

Excited to announce the expansion of our collaboration with Janssen Oncology US. Its a great example of how we can leverage multi-modal datasets and #AI to improve patient care, bringing the right #clinicaltrial to the right patient at the right time. tempus.com/tempus-announc…

We are thrilled to launch a data collaboration with Bristol Myers Squibb (Bristol Myers Squibb) to mine large transcriptomic datasets with the aim of identifying better ways to treat patients with unmet needs. Head to the release for more info: tempus.co/3iPQiyl.

Why is it so important to people to compare #Miami to #SiliconValley ? Put your head down and build something awesome.

We're excited that Tempus is included on FORTUNE #changetheworld list, for having a positive social impact with our TIME Trial Program, which brings the right #clinicaltrials to the right patients at a location close to home. Read more: tempus.co/3v5a0fI

Tempus is proud to collaborate with Friends of Cancer Research on its #HRD Harmonization Project. Together, we're working on identifying concordance between assays that measure HRD and generating data to support patient and provider decisions. #WhatFriendsDoes

I leave Chicago for one winter and the snow follows me to LA…climate change is real folks!

Incredibly excited to announce Tempus N+, expanding our real-world data program into Neuropsychiatry. With better multi-modal datasets, we can enable personalized treatment decisions in mental health. businesswire.com/news/home/2022…

There’s nothing like the energy from #ASCO and we’re just getting started. More exciting data coming out tomorrow…be on the lookout 👀👀

Harnessing the power of multimodal data is a team sport and I’m continuously amazed at the clinical insights we can produce with our research partners. Together, we can make patient care more data-driven than ever before.

Historically, real-world DNA+RNA data wasn’t available at scale. Here’s just a few ways we can leverage new data modalities to improve cancer care.

I’m very excited to share our expanded collaboration with GSK to deliver on the promise of data-driven precision medicine. Together, we can use multimodal data and AI to improve drug discovery and development to improve patient outcomes. endpts.com/gsk-expands-ai…

With the right multimodal data, we can uncover more biomarkers that change the future of cancer care. This is the start of more innovation for #SCLC patients.

Great review and highlights the importance of using #multimodal data from metastatic disease to inform oncology drug development.

Incredible progress and promise for leveraging neoantigens to battle pancreatic cancer progression.